HIV /AIDS: NEW NANO ARV DRUGS ARE COMING,TO BE TAKEN ONCE A MONTH

PROF.DRRAM ,HIV/AIDS,SEX DISEASES,SEX WEAKNESS & ABORTION SPECIALIST 
profdrram@gmail.com,+917838059592,+919832025033 DELHI –NCR,INDIA 
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar 
FOLLOW ON TWITTER:www.twitter.com/profdrram 
.
For HIV & AIDS drugs compliance or regular intake of medicines is very important as if drug missed for some time resistance may develop and new drug has to be started.Secondly these drug should reach most reserved immune cells cd4,cd8 or cd10 or other lymphocytes so that reservoir of HIV is finished and it should act so nice within cell or good penetration to kill HIV VIRUS as nausea, vomiting diarhoea etc should not reduce its amount in blood.Agai if less amount of ARV MEDICINES will go in blood so less will be adverse reactions.
Therefore long acting ARV MEDICINES LIKE GSK744 integrase inhibitor and NNRI Rilpivinir researched but once these are tagged with Nano particles then these can be used once a month injection basis only.
There are two types of nanomedicines, Owen said: nanoscale-containing drugs and solid drug nanoparticles (SDNs).
Nanoscale-containing drugs are often called "drug-delivery vehicles" because they are carriers that can either be loaded with antiretrovirals or surface-functional groups with antiretrovirals. They can be diverse, ranging from inorganic, insoluble nanoparticle carriers (such as gold nanoparticles) to lipid-based nanoparticles (such as liposomes) to organic polymeric nanoparticles (such as dendrimers).
SDNs, often called "nanosuspensions," are very small particles of the solid drugs themselves. Each of these particles is about one millionth the size of a human hair. They can be made either by milling, in which a solid chunk of a drug is ground down until it's nano-sized, or via the precipitation of solutions to form nano-sized versions of the drug.
There are different drivers for and against researching and developing nanomedicines, but the pros outweigh the cons, Owen asserted. On the downside, there can be issues with insolubility of active pharmaceutical ingredients, and the difficulty and cost of formulation during development can be high.
Pre-clinical research has shown that nano-formulations have greater potency at lower dosage levels than conventional formulations. Furthermore, with intramuscular or intravenous delivery, there could be a sustained release of the drug and better targeting of the virus.
For one thing, treatment interruptions won't be possible, which is particularly a concern when the need arises to manage an acute event (such as surgery or coinfection), pregnancy or the patient's desire to take a drug holiday.
There also are no strategies yet for how to manage drug-drug interactions between long-acting antiretrovirals. Furthermore, we don't yet know how appropriate long-acting drugs would be for patients with high viral loads. But hopefully with more research and trials, these concerns can be addressed.
Because of the smaller particle size of nanomedicines, they can better penetrate and target HIV where it lives, as opposed to the systemic approach that current conventional, oral formulations take, Owen said. With passive targeting, particularly at cellular and tissue sites, there can be size-influenced penetration of nanoparticles into lymph nodes where HIV can be hard to reach.
Additionally, there are active targetingopportunities: For instance, nanomedicines could be armed with special receptors, such as a range of cell-specific protein receptors that target HIV replication-competent cells, or tissue-specific protein receptors that may improve distribution into HIV reservoir sites.
more than 73% of patients indicated they would definitely or probably try injectable antiretroviral therapy. In terms of dose frequency, 61% were interested in weekly, 72% every two weeks and 84% monthly.
Therefore, there is overwhelming support from the patients themselves, particularly if nano-formulations can improve adherence, lower pill burden and cost, and ultimately improvequality of life.